‘Atypical’ Antidepressants in Overdose

Clinical Considerations with Respect to Safety

Drug Safety volume 26, pages539–551(2003)Cite this article

Abstract

The ‘atypical’ antidepressants comprise a heterogenous class with wide variation in presentation and management during overdose, both when compared with each other and with more traditional agents.

Further toxico-epidemiological data are required to make definitive predictions about the clinical effects of most of these agents in overdose. Here, however, we review the available information in a manner intended to benefit both prescribers and clinical toxicologists.

Our conclusion is that there can be no generic response by medical practitioners as to the ‘safety’ of these new antidepressants. Though undoubtedly exhibiting fewer problems in specific areas than some of the older classes of agents (e.g. arrhythmias with tricyclic antidepressants) each nonetheless presents unique safety problems.

We experienced great difficulty obtaining accurate information from the manufacturers about the animal toxicity data upon which their recommended human dose limits were set. This highlights the uncertainties involved with too readily making ‘safety’ claims about these agents.

The decision to prescribe ‘atypical’antidepressant medications alleged to be both efficacious and safe in overdose involves a medicolegal tension. This tension is between respecting patient autonomy through frank communication of the material risk of overdose and non-disclosure to avoid such harm.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 49.95

Tax calculation will be finalised during checkout.

Table I

References

  1. 1.

    Bulik CM, Carpenter LL, Kupfer DJ, et al. Features associated with suicide attempts in recurrent major depression. J Affect Disord 1990; 18(1): 29–37

    PubMed  CAS  Article  Google Scholar 

  2. 2.

    Boardman AP, Healy D. Modelling suicide risk in affective disorders. Eur Psychiatry 2001; 16(7): 400–5

    PubMed  CAS  Article  Google Scholar 

  3. 3.

    Farmer R. Epidemiology of suicide. Int Clin Psychopharmacol 1992; 6Suppl. 6: 1–11

    PubMed  Article  Google Scholar 

  4. 4.

    Goldney RD, Fisher LJ, Wilson DH, et al. Suicidal ideation and health-related quality of life in the community. Med J Aust 2001; 175(10): 546–9

    PubMed  CAS  Google Scholar 

  5. 5.

    de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43Suppl. 2: 40–6

    PubMed  Article  Google Scholar 

  6. 6.

    Swinkels JA, de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995; 9Suppl. 4: 19–25

    PubMed  Article  Google Scholar 

  7. 7.

    Buckley NA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf 1998; 18(5): 369–81

    PubMed  CAS  Article  Google Scholar 

  8. 8.

    Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992; 268(24): 3441–5

    PubMed  CAS  Article  Google Scholar 

  9. 9.

    Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310(6974): 221–4

    PubMed  CAS  Article  Google Scholar 

  10. 10.

    Frommer DA, Kulig KW, Marx JA, et al. Tricyclic antidepressant overdose: a review. JAMA 1987; 257(4): 521–6

    PubMed  CAS  Article  Google Scholar 

  11. 11.

    Power A. Drug treatment of depression: citalopram in overdose may result in serious morbidity and death. BMJ 1998; 316(7127): 307–8

    PubMed  CAS  Article  Google Scholar 

  12. 12.

    Hale AS. Citalopram is safe. BMJ 1998; 316(7147): 1825

    PubMed  CAS  Article  Google Scholar 

  13. 13.

    Gerritsen AW. Safety in overdose of mirtazapine: a case report. J Clin Psychiatry 1997; 58(6): 271

    PubMed  CAS  Article  Google Scholar 

  14. 14.

    Beerworth EE, Tiller JW. Liability in prescribing choice: the example of the antidepressants. Aust NZ J Psychiatry 1998; 32(4): 560–6

    CAS  Article  Google Scholar 

  15. 15.

    Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59Suppl. 15: 42–8

    PubMed  CAS  Google Scholar 

  16. 16.

    Baldwin DS. Adverse drug reactions to newer antidepressants. Adverse Drug Reaction Bulletin 2000; 200: 763–6

    Article  Google Scholar 

  17. 17.

    Gillman PK. Relative toxicity of antidepressants. Aust NZ J Psychiatry 1999; 33(3): 444

    CAS  Google Scholar 

  18. 18.

    Buckley NA. Poisoning and epidemiology: ‘Toxicoepidemiology’. Clin Exp Pharmacol Physiol 1998; 25: 198–205

    Article  Google Scholar 

  19. 19.

    Williams JWJ, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Int Med 2000; 132(9): 743–56

    PubMed  CAS  Google Scholar 

  20. 20.

    Hernandez JL, Ramos FJ, Infante J, et al. Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 2002; 36(4): 641–3

    PubMed  Article  Google Scholar 

  21. 21.

    Demers JC, Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. Ann Pharmacother 2001; 35(10): 1217–20

    PubMed  CAS  Article  Google Scholar 

  22. 22.

    Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics 2001; 42(3): 258–60

    PubMed  CAS  Article  Google Scholar 

  23. 23.

    Benazzi F. Serotonin syndrome with mirtazapine-fluoxetine combination. Int J Geriatr Psychiatry 1998; 13(7): 495–6

    PubMed  CAS  Article  Google Scholar 

  24. 24.

    de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57Suppl. 4: 19–25

    PubMed  Google Scholar 

  25. 25.

    Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51(3): 267–85

    PubMed  CAS  Article  Google Scholar 

  26. 26.

    Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38(6): 461–74

    PubMed  CAS  Article  Google Scholar 

  27. 27.

    Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry 1998; 59(5): 233–5

    PubMed  CAS  Article  Google Scholar 

  28. 28.

    Hoes MJ, Zeijpveld JH. First report of mirtazapine overdose. Int Clin Psychopharmacol 1996; 11(2): 147

    PubMed  CAS  Google Scholar 

  29. 29.

    Holzbach R, Jahn H, Pajonk FG, et al. Suicide attempts with mirtazapine overdose without complications. Biol Psychiatry 1998; 44(9): 925–6

    PubMed  CAS  Article  Google Scholar 

  30. 30.

    Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10Suppl. 4: 37–45

    PubMed  Article  Google Scholar 

  31. 31.

    Raja M, Azzoni A. Mirtazapine overdose with benign outcome. Eur Psychiatry 2002; 17(2): 107

    PubMed  CAS  Article  Google Scholar 

  32. 32.

    Retz W, Maier S, Maris F, et al. Non-fatal mirtazapine overdose. Int Clin Psychopharmacol 1998; 13(6): 277–9

    PubMed  CAS  Article  Google Scholar 

  33. 33.

    Velazquez C, Carlson A, Stokes KA, et al. Relative safety of mirtazapine overdose. Vet Hum Toxicol 2001; 43(6): 342–4

    PubMed  CAS  Google Scholar 

  34. 34.

    Schaper A, Farber E, Ebbecke M, et al. Suicide with mirtazapine — hardly possible. J Toxicol Clin Toxicol 2002; 40(3): 343–4

    Google Scholar 

  35. 35.

    Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332–3

    PubMed  Article  Google Scholar 

  36. 36.

    Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13(1): 100–9

    PubMed  CAS  Article  Google Scholar 

  37. 37.

    Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17(1): 10–21

    PubMed  CAS  Google Scholar 

  38. 38.

    Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51(3): 237–54

    PubMed  CAS  Article  Google Scholar 

  39. 39.

    Khalifa M, Daleau P, Turgeon A. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; 291(1): 280–4

    PubMed  CAS  Google Scholar 

  40. 40.

    Patat A, Troy S, Burke J, et al. Absolute bioavailability and electroencephalographic effects of conventional and extendedrelease formulations of venlafaxine in healthy subjects. J Clin Pharmacol 1998; 38(3): 256–67

    PubMed  CAS  Google Scholar 

  41. 41.

    Troy SM, DiLea C, Martin PT, et al. Pharmacokinetics of oncedaily venlafaxine extended release in healthy volunteers. Curr Ther Res 1997; 58(8): 504–14

    CAS  Article  Google Scholar 

  42. 42.

    Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12Suppl. 1: 30–44

    PubMed  Article  Google Scholar 

  43. 43.

    Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355(9207): 911–8

    PubMed  CAS  Article  Google Scholar 

  44. 44.

    Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16(3 Suppl. 2): 54S–9S

    PubMed  CAS  Article  Google Scholar 

  45. 45.

    Levine B, Jenkins AJ, Queen M, et al. Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 1996; 20(6): 502–5

    PubMed  CAS  Google Scholar 

  46. 46.

    Parsons AT, Anthony RM, Meeker JE. Two fatal cases of venlafaxine poisoning. J Anal Toxicol 1996; 20(4): 266–8

    PubMed  CAS  Google Scholar 

  47. 47.

    Woo OF, Vredenburg M, Freitas P, et al. Seizures after venlafaxine overdose: a case report. J Toxicol Clin Toxicol 1995; 33(5): 549–50

    Google Scholar 

  48. 48.

    Kokan L, Dart RC. Life threatening hypotension from venlafaxine overdose. Ann Emerg Med 1996; 27(6): 815

    Google Scholar 

  49. 49.

    Colbridge MG, Volans GN. Venlafaxine in overdose — experience of the National Poisons Information Service (London Centre). J Toxicol Clin Toxicol 1999; 37(3): 383

    Google Scholar 

  50. 50.

    Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine in overdose compared to serotonin specific reuptake inhibitors and tricyclic antidepressants. Q J Med 2003; 96: 369–74

    CAS  Article  Google Scholar 

  51. 51.

    Herrington LF, Gorman SE. Pediatric ingestion of Effexor (venlafaxine). J Toxicol Clin Toxicol 1996; 34(5): 558

    Google Scholar 

  52. 52.

    Banham ND. Fatal venlafaxine overdose. Med J Aust 1998; 169(8): 445, 448

    PubMed  Google Scholar 

  53. 53.

    Thorsson B, Snook C, Thorgeirsson G. Survival after prolonged cardiac arrest from venlafaxine (abstract 125). J Toxicol Clin Toxicol 2000; 38(2): 246–7

    Google Scholar 

  54. 54.

    Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999; 18(5): 309–13

    PubMed  CAS  Article  Google Scholar 

  55. 55.

    Buckley NA, Dawson AH, Reith DA. Controlled release drugs in overdose: clinical considerations. Drug Saf 1995; 12(1): 73–84

    PubMed  CAS  Article  Google Scholar 

  56. 56.

    Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998; 16(4): 615–9

    PubMed  CAS  Article  Google Scholar 

  57. 57.

    Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol. 1997; 17Suppl. 1: 2S–18S

    PubMed  CAS  Article  Google Scholar 

  58. 58.

    Cyr M, Brown CS. Nefazodone: its place among antidepressants. Ann Pharmacother 1996; 30(9): 1006–12

    PubMed  CAS  Google Scholar 

  59. 59.

    Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53(4): 608–36

    PubMed  CAS  Article  Google Scholar 

  60. 60.

    Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997; 33(4): 260–75

    PubMed  CAS  Article  Google Scholar 

  61. 61.

    Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995; 35(8): 830–9

    PubMed  CAS  Google Scholar 

  62. 62.

    Benson BE, Mathiason M, Dahl B, et al. Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med 2000; 18(5): 587–92

    PubMed  CAS  Article  Google Scholar 

  63. 63.

    Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57Suppl. 2: 31–8

    PubMed  CAS  Google Scholar 

  64. 64.

    Catalano G, Catalano MC, Tumarkin NB. Nefazodone overdose: a case report. Clin Neuropharmacol 1999; 22(1): 63–5

    PubMed  CAS  Article  Google Scholar 

  65. 65.

    John L, Perreault MM, Tao T, et al. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 1997; 29(2): 287–9

    PubMed  CAS  Article  Google Scholar 

  66. 66.

    McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother. 2001; 35(7-8): 870–3

    PubMed  CAS  Article  Google Scholar 

  67. 67.

    Peak DA. Toxic effects of nefazodone. Ann Emerg Med 1997; 30(4): 551

    PubMed  CAS  Article  Google Scholar 

  68. 68.

    Smith DL, Wenegrat BG. A case report of serotonin syndrome associated with combined nefazodone and fluoxetine. J Clin Psychiatry 2000; 61(2): 146

    PubMed  CAS  Article  Google Scholar 

  69. 69.

    Brazelton T, Blanc PD, Olson KR. Toxic effects of nefazodone. Ann Emerg Med 1997; 30(4): 550–1

    PubMed  CAS  Article  Google Scholar 

  70. 70.

    Schrader GD, Roberts-Thompson IC. Adverse effect of nefazodone: hepatitis. Med J Aust 1999; 170(9): 452

    PubMed  CAS  Google Scholar 

  71. 71.

    Scates AC, Doraiswamy PM. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000; 34(11): 1302–12

    PubMed  CAS  Article  Google Scholar 

  72. 72.

    Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39(6): 413–27

    PubMed  CAS  Article  Google Scholar 

  73. 73.

    Fleishaker JC, Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001; 70(3): 261–9

    PubMed  CAS  Article  Google Scholar 

  74. 74.

    Reboxetine — another new antidepressant. Drug Ther Bull 1998; 36(11):86–8

    Google Scholar 

  75. 75.

    Burns MJ. The Pharmacology and toxicology of reboxetine. Internet Journal of Medical Toxicology 2000; 3(4): 26

    Google Scholar 

  76. 76.

    Griffith JD, Carranza J, Griffith C, et al. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983; 44(5 Pt 2): 206–8

    PubMed  CAS  Google Scholar 

  77. 77.

    Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49(7): 262–6

    PubMed  CAS  Google Scholar 

  78. 78.

    Findlay JW, Van Wyck FJ, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981; 21(2): 127–35

    PubMed  CAS  Article  Google Scholar 

  79. 79.

    Laizure SC, DeVane CL, Stewart JT, et al. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38(5): 586–9

    PubMed  CAS  Article  Google Scholar 

  80. 80.

    Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28(10): 1176–83

    PubMed  CAS  Google Scholar 

  81. 81.

    Tucker Jr WE. Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 1983; 44(5 Pt 2): 60–2

    PubMed  CAS  Google Scholar 

  82. 82.

    Wang CM, Parker Jr CH, Maxwell RA. Electrophysiological effects of antidepressants on mammalian hearts and crayfish giant axon. J Cardiovasc Pharmacol 1981; 3(1): 101–12

    PubMed  CAS  Article  Google Scholar 

  83. 83.

    Spiller HA, Ramoska EA, Krenzelok EP, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994; 12(1): 43–5

    PubMed  CAS  Article  Google Scholar 

  84. 84.

    Rohrig TP, Ray NG. Tissue distribution of bupropion in a fatal overdose. J Anal Toxicol 1992; 16(5): 343–5

    PubMed  CAS  Google Scholar 

  85. 85.

    Shrier M, Diaz JE, Tsarouhas N. Cardiotoxicity associated with bupropion overdose. Ann Emerg Med 2000; 35(1): 100

    PubMed  CAS  Article  Google Scholar 

  86. 86.

    Friel PN, Logan BK, Fligner CL. Three fatal drug overdoses involving bupropion. J Anal Toxicol 1993; 17(7): 436–8

    PubMed  CAS  Google Scholar 

  87. 87.

    Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997; 35(3): 321–4

    PubMed  CAS  Article  Google Scholar 

  88. 88.

    Tracey JA, Cassidy N, Casey PB, et al. Bupropion (Zyban) toxicity. Ir Med J 2002; 95(1): 23–4

    PubMed  CAS  Google Scholar 

  89. 89.

    Colbridge MG, Dargan PI, Jones AL. Bupropion — the experience of the National Poisons Information Service (London). J Toxicol Clin Toxicol 2002; 40(3): 398–9

    Google Scholar 

  90. 90.

    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11): 450–6

    PubMed  CAS  Google Scholar 

  91. 91.

    Paris PA, Saucier JR. ECG conduction delays associated with massive bupropion overdose. J Toxicol Clin Toxicol 1998; 36(6): 595–8

    PubMed  CAS  Article  Google Scholar 

  92. 92.

    Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50(7): 256–61

    PubMed  CAS  Google Scholar 

  93. 93.

    Velez LI, Delaney KA, Rivera W, et al. Delayed status epilepticus after a sustained release bupropion overdose. J Toxicol Clin Toxicol 2002; 403): 323–4

    Google Scholar 

  94. 94.

    Falkland M, McMorrow J, McKeown R, et al. Bupropion SR in overdose: subsidized poisoning. J Toxicol Clin Toxicol 2002; 40(3): 275–6

    Google Scholar 

  95. 95.

    Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin. Planta Med 1984; 50(3): 272–4

    PubMed  CAS  Article  Google Scholar 

  96. 96.

    Pepping J. St. John’s wort: Hypericum perforatum. Am J Health Syst Pharm 1999; 56(4): 329–30

    PubMed  CAS  Google Scholar 

  97. 97.

    Di Carlo G, Borrelli F, Izzo AA, et al. St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 2001; 22(6): 292–7

    PubMed  Article  Google Scholar 

  98. 98.

    Perovic S, Muller WE. Pharmacological profile of hypericum extract: effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 1995; 45 (11): 1145–8

    Google Scholar 

  99. 99.

    Southwell IA, Bourke CA. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John’s Wort). Phytochemistry 2001; 56(5): 437–41

    PubMed  CAS  Article  Google Scholar 

  100. 100.

    Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40(9): 2087–93

    PubMed  CAS  Google Scholar 

  101. 101.

    Woelk H, Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994; 7Suppl. 1: S34–8

    PubMed  Article  Google Scholar 

  102. 102.

    Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 2000; 321(7260): 536–9

    PubMed  CAS  Article  Google Scholar 

  103. 103.

    Balfour P. Use of hypericum as antidepressant: safety in overdose needs to be established. BMJ 2000; 320(7242): 1142–3

    PubMed  CAS  Google Scholar 

  104. 104.

    Shannon M. Alternative medicines toxicology: a review of selected agents. J Toxicol Clin Toxicol 1999; 37(6): 709–13

    PubMed  CAS  Article  Google Scholar 

  105. 105.

    Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12(1): 7–10

    PubMed  CAS  Article  Google Scholar 

  106. 106.

    Bray BJ, Perry NB, Menkes DB, et al. St. John’s wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002; 66(1): 27–33

    PubMed  CAS  Article  Google Scholar 

  107. 107.

    Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John’s Wort. Am J Med 2002; 112(6): 507–8

    PubMed  Article  Google Scholar 

  108. 108.

    Isacsson G, Redfors I, Wasserman D, et al. Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden. BMJ 1994; 309(6968): 1546–9

    PubMed  CAS  Article  Google Scholar 

  109. 109.

    Gaffney PN, Schuckman HA, Beeson MS. Nefazodone overdose. Ann Pharmacother 1998; 32(11): 1249–50

    PubMed  CAS  Article  Google Scholar 

  110. 110.

    Hawton K, Simkin S, Deeks JJ, et al. Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study. BMJ 1999; 318(7189): 972–7

    PubMed  CAS  Article  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Affiliations

  1. Department of Clinical Toxicology and Pharmacology, The Canberra Hospital, PO Box 11, Woden, ACT 2606, Australia

    Dr Nicholas A. Buckley & Thomas A. Faunce

Authors
  1. Dr Nicholas A. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Faunce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dr Nicholas A. Buckley.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buckley, N.A., Faunce, T.A. ‘Atypical’ Antidepressants in Overdose. Drug-Safety 26, 539–551 (2003). https://doi.org/10.2165/00002018-200326080-00002

Download citation

Keywords

  • Venlafaxine
  • Bupropion
  • Mirtazapine
  • Hypericin
  • Nefazodone